目的 探究前列地爾聯(lián)合倍他司汀治療鉑類化療藥物所致耳源性眩暈的療效。方法 選取2017年8月—2019年11月河南科技大學第一附屬醫(yī)院收治的85例鉑類化療腫瘤患者且出現(xiàn)耳源性眩暈者，隨機分為對照組（42例）和治療組（43例）。對照組靜脈滴注鹽酸倍他司汀注射液，10 mg/次，1次/d。治療組在對照組基礎上靜脈滴注前列地爾注射液，1 mL/次，1次/d。兩組均治療14 d。觀察兩組的臨床療效，比較兩組眩暈障礙評定量表評分和生活質量評分。結果 治療后，治療組總有效率93.02%，顯著高于對照組的76.19%（P<0.05）。治療后，兩組眩暈障礙評定量表評分均較治療前顯著降低，而生理機能、生理職能、情感職能評分均顯著升高（P<0.05）；治療后，治療組眩暈障礙評定量表評分低于對照組，但生理機能、生理職能、情感職能評分高于對照組（P<0.05）。結論 前列地爾聯(lián)合倍他司汀治療鉑類化療藥物所致耳源性眩暈療效較好，可有效改善臨床癥狀，提高了生活質量，具有一定的臨床推廣應用價值。

Objective To explore the clinical efficacy of alprostadil combined with betastastine in treatment of otogenic vertigo induced by platinum-class chemotherapy drugs. Methods A total of 85 patients with platinum-type chemotherapy tumor with otogenic vertigo admitted to the First Affiliated Hospital of Henan University of Science and Technology from August 2017 to November 2019 were selected and randomly divided into control group (42 cases) and treatment group (43 cases). Patients in the control group were iv administered with Betahistine Hydrochloride Injection, 10 mL/time, once daily. Patients in the treatment group were iv administered with Alprostadil Injection on the basis of the control group, 1 mL/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the vertigo disorder rating scale score and life quality score were compared between two groups. Results After treatment, the total effective rate of the treatment group was 93.02%, which was significantly higher than that of the control group (76.19%, P<0.05). After treatment, the scores of vertigo disorder rating scale in both groups were significantly decreased compared with before treatment, but the scores of physiological function, physiological function and emotional function were significantly increased (P<0.05). After treatment, the scores of vertigo disorder rating scale in the treatment group were lower than those in the control group, but the scores of physiological function, physiological function and emotional function in the treatment group were higher than those in the control group (P<0.05). Conclusion Alprostadil combined with betastastine has curative effect in treatment of otogenic vertigo induced by platinum-class chemotherapy drugs, and can effectively improve the clinical symptoms, and improve the life quality, which has a certain value of clinical application.

R971